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The healthy ageing gene expression
signature for Alzheimer’s disease diagnosis: a
random sampling perspective
Laurent Jacob1* and Terence P. Speed2
Abstract
In a recent publication, Sood et al. (Genome Biol 16:185, 2015) presented a set of 150 probe sets that could be used in
the diagnosis of Alzheimer’s disease (AD) based on gene expression. We reproduce some of their experiments and
show that their signature is indeed able to discriminate between AD and control patients using blood gene
expression in two cohorts. We also show that its performance does not stand out compared to randomly sampled
sets of 150 probe sets from the same array.
Sood et al. built a signature by identifying 150 probe
sets that predict chronological age on a gene expression
dataset of muscle samples [1]. The 150 probe sets selected
constitute the healthy ageing gene signature (HAGS) and
were used in a 5-nearest-neighbor classifier to predict the
chronological age or Alzheimer’s disease (AD) status of
samples in other studies.
We focused on the AD status prediction experiments.
We aimed to use the same labels and subset of samples
from each cohort as used in Sood et al. [1] but cannot be
certain as we do not have the authors’ code.
In their Figure 5, Sood et al. report areas under the
receiver operating characteristic curve (AUCs) of 0.73 and
0.66 using the HAGS for AD in cohorts 1 and 2, respec-
tively [1].We estimate the AUC of two 5-nearest-neighbor
classifiers by leave-one-out cross validation (LOOCV) on
a randomly sampled 50% of each dataset (stratified by
status). One classifier uses the HAGS and the other one
uses a randomly sampled 150 probe sets. We repeat the
operation 1000 times, using a new random selection of
probe sets for each repetition. More details of our experi-
ments including patient selection, grouping, and sampling
*Correspondence: laurent.jacob@univ-lyon1.fr
1Université de Lyon, Université Lyon 1, and CNRS, UMR 5558, Laboratoire de
Biométrie et Biologie Evolutive, Villeurbanne, France
Full list of author information is available at the end of the article
schemes are available in Additional file 1. We also provide
the R code used in these experiments as Additional file 2.
Figure 1 shows that the distribution of the performance
obtained by the HAGS and by random sets of 150 probe
sets are very similar. This suggests that we should expect
similar AD status prediction performance for the HAGS
and random sets of probes on average for patients from
the same distributions of the phenotype, conditional to
the expression of all probes, as these cohorts.
We also assessed whether the HAGS stands out from
random signatures by looking at its median performance
across random samplings from the cohorts. We drew 500
random sets of 150 probe sets, and used each of these ran-
dom sets on the same 200 stratified samplings of 50% of
the cohorts. If each of the 500 sets of 150 probe sets per-
forms well by chance on a few of the 200 sub-samplings
but performs poorly on the others, we would expect the
median AUC of the HAGS across the 200 subsamples to
stand out from the distribution of median AUCs obtained
using the 500 random sets of probe sets. Figure 2 shows
that this is not the case: the median AUC obtained using
theHAGS lies within the interquartile range of themedian
AUCs obtained using random sets of probe sets.
That the random probe sets perform as well as a set
of probes that were selected for their predictive power
on a different dataset is not too surprising. Ein-Dor et al.
noted that sampling from a small set of arrays leads to
the selection of different gene expression signatures for
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Fig. 1 Area under the receiver operating characteristic curves. This was obtained by LOOCV of a 5-nearest-neighbor classifier over 1000 random
selections of 50% of the arrays, using the HAGS probe sets (.sig suffix) and a new random selection of 150 probe sets each time (.rand suffix), over
the two AD cohorts. AD Alzheimer’s disease, AUC area under the receiver operating characteristic curve, HAGS healthy ageing gene signature,
LOOCV leave-one-out cross validation
breast cancer prognosis [2]. Haury et al. found no signifi-
cant difference between the AUCs obtained using random
signatures and signatures selected for their predictive per-
formance [3]. Our finding that randomly selected sets
of probes perform as well as the HAGS on average is
consistent with their observation.
The AUCs published in Sood et al. [1] are the prod-
uct of two factors: the predictive value of the 150 probe
sets selected (HAGS) and the difficulty of the prediction
problems on which they are assessed: discriminating
between 25- and 65-year-old patients or between control
and AD patients on these particular datasets. Our random
sampling experiments suggests that the AUCs presented
are not exceptionally high given the intrinsic difficulty of
the prediction problems. In particular, there is no reason
to believe that the selection protocol (identifying genes
Fig. 2Median area under the receiver operating characteristic curves. This was obtained by LOOCV of a 5-nearest-neighbor classifier across 200
random selections of 50% of the arrays, using the HAGS probe sets (green dots) and 500 random selections of 150 probe sets (box plots), over the
two AD cohorts. AD Alzheimer’s disease, AUC area under the receiver operating characteristic curve, HAGS healthy ageing gene signature, LOOCV
leave-one-out cross validation
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that discriminate 15 healthy young from 15 healthy old
patients) picked up an exceptionally predictive signal for
healthy ageing.
A principal component analysis of either cohort actu-
ally reveals that the first principal component explains
about 25% of the total variance and separates the two
status groups rather well. A possible explanation is an
unobserved confounding variable associated with both
gene expression measurements and AD status. Another
possibility is that the problem of discriminating between
controls and patients diagnosed with AD from blood gene
expression is actually a feasible one because the presence
of AD at this stage has a sufficiently strong effect on the
overall gene expression. In this case, the question moves
to deciding whether a good predictor of current AD status
is also a good predictor of future AD status. The lat-
ter is arguably a more important objective [4], allowing
mass population screenings to detect those at risk, but
could prove more difficult than the former as it may be
associated with more subtle effects on gene expression.
Our discussion underscores the importance of con-
sidering random sampling perspectives when building a
gene signature, especially when interpreting its content
or studying its overlap with other signatures, not just its
predictive power.
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